Matricelf Ltd. Logo

Matricelf Ltd.

Develops autologous, patient-specific tissue implants for regenerative medicine.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion

Description

Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

genOway Logo
Designs and develops genetically modified preclinical models for research.
France
ALGEN
Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.